Calidi Biotherapeutics Inc’s filing revealed that its CEO and Chairman of the Board Camaisa Allan unloaded Company’s shares for reported $16200.0 on Dec 17 ’24. In the deal valued at $1.62 per share,10,000 shares were sold. As a result of this transaction, Camaisa Allan now holds 66,712 shares worth roughly $37358.72.
H.C. Wainwright initiated its Calidi Biotherapeutics Inc [CLDI] rating to a Buy in a research note published on November 22, 2023; the price target was $11. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in early October with a ‘”an Outperform”‘ rating.
Price Performance Review of CLDI
On Tuesday, Calidi Biotherapeutics Inc [AMEX:CLDI] saw its stock fall -1.61% to $0.56. Over the last five days, the stock has lost -19.91%. Calidi Biotherapeutics Inc shares have fallen nearly -51.56% since the year began. Nevertheless, the stocks have fallen -90.14% over the past one year. While a 52-week high of $8.30 was reached on 02/12/25, a 52-week low of $0.56 was recorded on 04/01/25. SMA at 50 days reached $0.9130, while 200 days put it at $1.3603.
Levels Of Support And Resistance For CLDI Stock
The 24-hour chart illustrates a support level at 0.5160, which if violated will result in even more drops to 0.4749. On the upside, there is a resistance level at 0.6123. A further resistance level may holdings at 0.6675. The Relative Strength Index (RSI) on the 14-day chart is 30.41, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.1399, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.28%. Stochastics %K at 11.00% indicates the stock is a buying.
